Global X S&P Biotech ETF (ASX:CURE)
Australia · Delayed Price · Currency is AUD 63.26
+0.03 (0.05%)
May 12, 2026, 3:01 PM AEST
52.07% (1Y)
| Assets | 41.47M |
| Expense Ratio | 0.45% |
| PE Ratio | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +51.92% |
| Volume | 157 |
| Open | 62.60 |
| Previous Close | 63.23 |
| Day's Range | 62.60 - 63.26 |
| 52-Week Low | 40.17 |
| 52-Week High | 65.95 |
| Beta | 0.33 |
| Holdings | 10 |
| Inception Date | Nov 8, 2018 |
About CURE
The Global X S&P Biotech ETF (CURE) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S&P Biotechnology Select Industry Index.
Asset Class Equity
Category Health Care
Stock Exchange Australian Securities Exchange
Ticker Symbol CURE
Provider Global X
Index Tracked S&P Biotechnology Select Industry
Performance
CURE had a total return of 51.92% in the past year, including dividends. Since the fund's inception, the average annual return has been 6.68%.
Top Holdings
15.05% of assets| Name | Symbol | Weight |
|---|---|---|
| Cash | n/a | 2.00% |
| TG Therapeutics, Inc. | TGTX | 1.69% |
| Travere Therapeutics, Inc. | TVTX | 1.60% |
| Revolution Medicines, Inc. | RVMD | 1.58% |
| Alkermes plc | ALKS | 1.40% |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1.39% |
| Beam Therapeutics Inc. | BEAM | 1.37% |
| Twist Bioscience Corporation | TWST | 1.35% |
| Cytokinetics, Incorporated | CYTK | 1.34% |
| Krystal Biotech, Inc. | KRYS | 1.33% |